Project Carpaccio: MeaTech Makes Real 3D Printed Meat

The proof may often be found in the pudding, but adventurous eaters may also discover it in evolved food production like Project Carpaccio, as MeaTech Ltd. outpaces other companies in bioprinting “real, clean meat” with muscle and fat cells derived from animals. Recently announcing that their researchers have reached their ambitious goal of bioprinting stem cells that “successfully fused” in a layer of meat, the Israeli startup has reached the first step necessary in their goal to fabricate a quarter-pound steak with progressive technology that eliminates the butchering of animals.

Consumers around the world should continue to find their epicurean expectations transformed as startups continue to make alternative meats palatable. You may already be surprised to see vegetarian and vegan food, along with plant-based ‘burgers,’ making their way onto mainstream menus these days—from the Beyond Burger which you may have encountered at local restaurants to the much-discussed Impossible Whopper now available at Burger King.

Other fast-food corporations are actively engaged in R&D, racing to promote their own versions of the enhanced veggie burger too. Meat alternatives are blossoming into an impressive industry of their own, expected to be valued at around $8.1 billion by 2026. Such foods and snacks processed by conventional methods are often made from soy, wheat, or other types of alternative vegan proteins like seitan.

MeaTech, however, has developed a comprehensive process for 3D printing meat that actually comes directly from animals. MeaTech scientists begin by taking umbilical cord samples (leaving animals unharmed) from animals like cows and then developing the cells into a continuous line of production. As the researchers are tasked with separating fat and muscle cells, they mark them by using different types of bioink for bioprinting—with the cells then incubating and growing into viable products for consumption.

MeaTech’s 3D meat printer. (Image: PR)

Project Carpaccio came to fruition as scientists from MeaTech 3D printed meat from stem cells using a 3D printer that they customized in their own lab. Sorting and separating cells was no easy feat as they worked to create a texture similar to real meat, along with making the appropriate ink and then fusing the materials.

(Image: MeaTech)

(Image: MeaTech)

Companies experimenting with and exploring the future potential of 3D printed meat are beginning to multiply. Consumers may still feel some trepidation about eating anything bearing the vegetarian label (or at the next level, vegan), and even more so regarding food that is extruded from a 3D printer; however as 3D printing technology continues to infiltrate the mainstream, other companies too like Novameat and Redefine Meat are working to bring forth compelling products to dinner tables around the world.

“This is another step on the path to meeting the company’s vision of building a plant for the growing and manufacturing of 3D-printed cuts of meat without needing to slaughter or harm any animals, a technology which could dramatically reduce air pollution, loss of energy sources and the loss of vast areas currently used for raising livestock for slaughter,” said Sharon Fima, CEO and co-founder of MeaTech.

[Source: CTech]

The post Project Carpaccio: MeaTech Makes Real 3D Printed Meat appeared first on 3DPrint.com | The Voice of 3D Printing / Additive Manufacturing.

3DHEALS2020: A Not So Lonely Planet

Only a few weeks away from 3DHEALS2020, and I just got off the phone with one of our speakers, Dr. Ho, from NAMIC Singapore. Our brief interview reminded me just how much I enjoyed Singapore—its start-up like government, incredible universities, and its beautiful modern architecture, chili crabs, and unpredictable rainstorms. Now, I’m on my way to some of the best meals in my life with another 3DHEALS community event in a foreign city. Looking back, there are many stories like that: in Detroit, Vigo, Paris, Shanghai, or Boston, my work with 3DHEALS communities has been a journey of adventures and friendships. 3DHEALS2020 is really a way to summarize my travels from the last two years. It is my version of Lonely Planet—the healthcare 3D printing version.

I really felt more alive when people have welcomed me into their cities; when they have showed off their latest innovations; when they have bantered enthusiastically with one another in a local pub till midnight after 3DHEALS events. And they felt the same way.

Sadly, however, this pandemic is putting old methods of human connection into question. Perhaps, a virtual summit is a stopgap solution for conferences, but, more likely, it is time for us to explore alternative and better ways to stay connected and informed.

The virtual 3DHEALS2020 summit will be a good start.

While we can’t serve you delicious San Francisco Blue Bottle coffee, there are three things we aim to do right with this conference:

1. Awesome live content

One upside about the virtual summit is that people who could not be available due to logistic barriers are now more available. We added 20+ speakers since the pandemic began and are still adding more parallel workshops to the existing program. Some of highlights include:

A. Biofabrication/Bioprinting Panels and Workshops:

Welcome to the holy grail of healthcare 3D printing applications!

These panels and workshops collect some of the brightest minds in the world of tissue engineering, biofabrication, and bioprinting. It includes the newest generation of startup founders. Names such as Stephanie WillerthAdam FeinbergJordan Miller are already well-established and loved in the scientific communities and just founded their own startups within the last 12 months. More established startup founders whose companies are also critical to the eventual success of biofabrication, tissue engineering, and cell therapy at large will also join us live, including Melanie Mathieu from Prellis Biologics, Jon Rawley from Roosterbio, John O’Reily from Xylyx, Taciana Pereira from Allevi, and Kevin Caldwell from Ossium Health. Qrquidea Garcia (“Orchid”) from JNJ Innovation will also join us on this panel, discussing how an industry leader can work with innovators and startups in this exciting, burgeoning field.

B. Regulatory and Legal Landscape of Healthcare 3D Printing

For those who put their skin in the game, this is probably one of the most must-attend sessions. 3D printing in healthcare is a super new field, and legal experts in this field who have established track records and legitimacy are only a handful. This session will include the most comprehensive list of legal and regulatory concerns specifically for healthcare 3D printing, including intellectual property/patent issues, product liability, FDA pathways, manufacturing standards, and more. Steven Bauer, from FDA CBER, just joined the panel to directly address concerns related to cell therapy from the biofabrication and stem cell communities. The speakers are not just well-versed on how to interpret the law and policies, but also how to interact with scientists, policy makers, organizations, and standards bodies at this early stage of the industry, with practical, real-life examples.

C. Global Perspectives

One lesson from this pandemic is that globalization has consequences. Having a well-rounded worldview of the global healthcare 3D printing ecosystem is a requirement for future success. Our early morning sessions are reserved for international speakers all over the world to meet the audience and share their unique perspectives, needs, and hopes. Both America Makes director John Wilczynski and NAMIC director Dr. Chaw Sing Ho, along with experts from Turkey, India, and Taiwan, will share how healthcare innovations can thrive in both local and global environments. On day two (June 6th), the audience will learn about how different countries are implementing the concept of 3D printing for Point of Care, which cannot be taken out of context of different healthcare systems and cultures. The audience will meet and learn from the leaders at UCSFStanfordGermany (Kumovis), India (Anatomiz3D), and developing countries.

2. Pre- and post-event networking opportunities

The attendees will have the opportunity to meet other attendees, speakers, and conference organizers as soon as they sign up the event using a dedicated conference app. They can send direct messages, post threads, share photos, host their own virtual events days before the conference. The app will be available to registered attendees for six months after the conference ends.

3. Entrepreneurship

One of the most exciting aspects of 3DHEALS2020 is its focus on entrepreneurship. Pitch3D has been a quarterly free and online pitch platform to selected early-stage startups in healthcare 3D printing and bioprinting spaces for the last two years, introducing 30+ startups from all over the world to institutional investors. 3DHEALS2020 also gathered some of the most experienced VCs and entrepreneurs in the space to share their stories, perspectives, and directly engage with the startups and the 3DHEALS2020 attendees directly during both pitch sessions and investor panels. There will be ten startups pitching each day at 5-6 PM PST. Interested startups can apply here.

This is the time of uncertainty and change.

Join us at 3DHEALS2020, connect with the world, and take control of your future. This is a Not So Lonely Planet.

The post 3DHEALS2020: A Not So Lonely Planet appeared first on 3DPrint.com | The Voice of 3D Printing / Additive Manufacturing.

Polbionica Could Become the Next Success Story in Organ Bioprinting

Last year, a scientific team in Warsaw, Poland, bioprinted the world’s first prototype of a bionic pancreas with a vascular system. Led by clinical transplantation expert and inventor, Michał Wszoła, the specialists seek to introduce 3D bioprinting of the bionic pancreas to clinical practices worldwide in just over three years. The work, conducted at Polbionica, a spin-off company from the Foundation of Research and Science Development, will bring to market the research to 3D bioprint scaffolds using live pancreatic islands or insulin-producing cells to create a bionic pancreas, like the bioinks, bioreactor and the g-code files necessary to print bionic pancreas.

With more than 40 million people suffering from type I diabetes worldwide, this project holds a lot of promise. In Europe alone, seven million people are afflicted with the disease, with 700,000 of them undergoing serious complications.

The statistics alone offer a troubling overall pan of the disease. Even more so because, as Wszoła suggested in an interview with 3DPrint.com, hypoglycemia unawareness is a life-threatening complication that causes sudden death and is one of the major problems for type I diabetes; and the only method leading to a complete cure is a pancreas or pancreatic islet transplantation. But less than 200 pancreatic transplantations are carried out annually in Europe, which means that hundreds of people die while waiting for a transplant.

Polbionica is working to develop the key building blocks that support the development of the first bionic pancreas suitable for transplantation: bioink A for bioprinting bionic pancreas, bioink B for bioprinting vasculature, a novel bioreactor for growing organs, and a g-code file with specific bioprinting commands.

The company developed its own bioinks for this project and for bioprinting other organs of the body, while another bioink was used in 3D bioprinting of vessels with endothelial cells. Moreover, to carry out their research, they used Cellink‘s BioX bioprinter.

Bioreactor (Image: Polbionica)

According to Wszoła, the organ based on bioprinted 3D cell-laden bioinks, functional vessels, and pancreatic islets would restore the body’s ability to regulate blood sugar levels and revolutionize the treatment of diabetes.

For now, the scientific team has the ability to bioprint a living organ of 3x5x3.5 centimeters, which consists of more than 600,000 islets equivalent that are retrieved from the donor and considered to be the suitable amount to cure a person with diabetes.

“Our next step is to replace the pancreatic islets with stem cell-derived alpha and beta cells. With this approach, the patient would not have to wait for donor cells since the pluripotent stem cells being used are derived from their own tissues,” indicated Wszoła, who is also a transplant and general surgeon. “So far, studies on animals proved that the use of established products was safe.”

Scientists at work at the lab (Image: Polbionica)

“In order to reverse diabetes in humans, we need to have about one billion stem cells because efficacy to transform them into insulin-producing cells varies between 15% and 40%. I don’t believe that we will be able to solve the problem of brittle diabetes with transplantation of stem cell-derived islets (alpha and beta cells mixed into 3D organoids) alone,” he stated. “We should remember the lesson learned from pancreatic islet transplantation, whether we use original islets derived from a donor pancreas or produced from a patients’ stem cells, it will not solve the problem. In my opinion, we have to give those new islets a special nest, which involves an extracellular matrix through our bioinks and vessels with oxygen supply.”
Researchers at Polbionica have recently performed studies on mice proving that the bioprinted pancreatic petals using bioinks were well tolerated by the animals without any extended foreign body reaction to them. In April they will move onto studies with pigs and are planning studies with bigger animals together with Artur Kaminski, head of the Department of Transplantology and Central Tissue Bank at Warsaw Medical University.
“We expect clinical trials will be performed in Warsaw with the cooperation of our partners MediSpace Medical Centre and Warsaw Medical University. However, to begin this stage, we still have to overcome a few hurdles, like product stability, animal trials, approval from authorities as well as funding. If all that happens, just a few patients will be involved in the first stage of the clinical trial, mainly those who cannot receive any other treatment, and we have to remember that for the majority of people with diabetes, intensive insulin intake with CGM control is sufficient,” described Wszoła.
In 2012, diabetes expenses around the world accounted for 11% of the total health care expenditure. The Polish state needs close to one billion euros every year for diabetes. According to Wszoła, their potential competition, working on developing artificial pancreas is only offering a bridge treatment. Polbionica wants to go beyond that: their bionic pancreas could be a living organ that is a breakthrough in the treatment of type 1 diabetes.
He, along with his team hopes that their final product and know-how will solve problems related to the shortage of organs, postoperative complications and immunosuppression after transplantation, and above all, will be a chance to completely cure type 1 diabetes.
Moreover, the positive development of the organ production technology would significantly affect the general health of society, largely eliminating the problem of diseases associated with end-stage organ failure, reducing treatment costs, the need for social care, and professional absenteeism, while improving the quality of life of patients, and speeding up the process of introducing new drugs into the market.
“Bioprinting can have a great impact on the development of medicine, however, like every technology, it also has some limitations. We must remember that we are handling living cells, and the stress and other conditions which cells undergo during the bioprinting process has an influence on its function. Besides, we still have to work on better materials to build organs, materials that will keep cells together and allow them to function properly, materials with special strength, viscosity, and elascity,” claimed Wszoła.
The technology established by Polbionica even could let researchers bioprint vascularized organ models with cancer tumors to conduct research on the efficacy of newly implemented drugs. It may even revolutionize drug implementation routes and help diminish the need to perform animal studies.
“The field of drug testing can highly benefit from bioprinitng, with our technology we are now able to bioprint different pathologic models, such as pancreatic and liver cancers, melanomas, large bowel and breast cancer. We can also mimic microenvironments within tumors, print vessels and observe them in the lab when we add drugs and perform different analysis. In short, we can give a lot of answers and have an insight on drug development like never before.”

Polbionica is implementing the project as part of the Prevention Practises and Treatment of Civilization Diseases (STRATEGMED) program, funded by the Polish National Center for Research and Development. With experts in the fields of biotechnology, chemistry, mechatronics, bioprinting, and medicine, the team is moving forward quite rapidly in an area that to date has no cure, new technology can help patients reduce the burden of managing the condition, especially with regards to measuring their blood sugar levels and administering insulin, however, breakthroughs are not common. And although still in animal trials, the team is looking forward to the day when they will bioprint a bionic pancreas with living cells and tissues using their own bioinks.

The post Polbionica Could Become the Next Success Story in Organ Bioprinting appeared first on 3DPrint.com | The Voice of 3D Printing / Additive Manufacturing.

CELLINK and Uppsala University Send Stem Cells to Space

CELLINK and Uppsala University send stem cells to space

To study the influence of microgravity and hypergravity on living systems, bioprinting pioneer CELLINK, in collaboration with a team of scientists at Uppsala University, has sent 3D bioprinted boundary cap neural crest stem cells to space. The partnership is aiming to accelerate the development of a 3D neural stem cell system to provide insight on how gravity alterations influence cellular properties. According to the Department of Neuroscience at Uppsala University’s Faculty of Medicine, these so-called boundary cap neural crest stem cells are a transient cell population residing at the junction between dorsal roots and spinal cord during embryonic development. In 2014, researchers at the university conducted studies that showed how growth, survival and function of insulin-producing cells in the pancreas are promoted if the cells are cultured or transplanted together with boundary cap neural crest stem cells, providing novel opportunities to treat patients with type one diabetes.

The stem cells prior to launch

CELLINK’s BIO X bioprinter and bioinks were used to bioprint boundary cap neural crest stem cells that were successfully launched to space on June 24 on Maser14 by the Swedish National Space Agency. The cells were supplied by Uppsala University and printed using CELLINK Bioink and CELLINK GelMA.

CELLINK BIO X Bioprinter used by Uppsala University

“Our mission to help improve the physical conditions for astronauts with Uppsala University is a huge milestone for CELLINK. The strenuous conditions astronauts face while in space has been a widely talked about subject and this week we took the first step towards helping solve this problem. Understanding the effects of microgravity is a crucial element to this equation.  We have worked extremely hard on developing technology that will help change the world and are very much looking forward to sharing the first set of results as soon as they become available,” suggestedItedale Redwan, Chief Science Officer at CELLINK, to 3DPrint.com.

Space exploration challenges the limits of human physiology, and advancing capabilities in spaceflight require innovative solutions from frontline scientists across fields of physics, biology, and medicine. This is why CELLINK, the world’s first bioink company, continually seeks new partnerships and collaborations to provide researchers with emerging capabilities and innovations in the field. The startup has already managed to print human skin and is also working on producing liver tissues, as well as the beta cells that produce the insulin we need to survive.

This is not the first collaboration between CELLINK and Uppsala University, the company has worked with Associate Professor Joey Lau Börjesson to use 3D bioprinting to create a favourable microenvironment for transplanted insulin-producing cells. At the time Börjesson used 3D bioprinter INKREDIBLE to bioprint human pancreatic islets with CELLINK’s bioink PAN X, with extracellular matrix proteins derived from human pancreas and used to mimic the physiological microenvironment for the pancreatic islets of Langerhans (which have a dense network of blood vessels facilitating delivery of the produced hormones which regulate the blood glucose levels). The group mixed human islets with the PAN X bioink and bioprinted grid-shaped constructs, showing that the function in human islets is improved when bioprinted with the bioink; moreover, the human islets demonstrated intact morphology after bioprinting.

There are other projects to bioprint in space on the way, like nScrypt‘s 3D BioFabrication Facility (BFF) set to launch sometime this year to the International Space Station (ISS) aboard a cargo mission departing from the Air Force Station in Cape Canaveral, Florida. The first complete print, after the initial test prints, will be a cardiac patch for damaged hearts. While the Athlone Institute of Technology (AIT), under contract with the European Space Agency, will be creating a new, large-scale 3D printer capable of fabricating parts in a zero-gravity atmosphere. The innovative hardware will be used at the International Space Station (ISS) in connection with a European consortium to be known as ‘Project Imperial’ that includes Sonaca GroupBEEVERYCREATIVE, and OHB.

So, why is everyone so eager to send stem cells and bioprinters to space? For one, microgravity has an effect on astronauts health and stem cell research could shed light on what the effects of long missions in space could cause to the human body. In 2013, mouse embryonic stem cells were transported to the ISS to investigate the impact of long-term space flight on human health. This, like many other projects, arose after previous studies found astronauts and animals returning from space have damage to their immune or reproductive systems, which might be caused by microgravity, radiation or even stress. It seems that sending stem cells to space could not only help mitigate some of these factors but also aid in the development of new drugs to combat them.

Image Credit: CELLINK

Tel Aviv University: Researchers 3D Print Cardiac Patches & Cellularized Hearts

Researchers at Tel Aviv University continue to try to meet the ongoing challenges in cardiac tissue engineering. In ‘3D Printing of Personalized Thick and Perfusable Cardiac Patches and Hearts,’ authors Nadav Noor, Assaf Shapira, Reuven Edri, Idan Gal, Lior Wertheim, and Tal Dvir outline the steps they took to match technology with tissue.

Cardiovascular disease is the leading killer of patients in the US, and organ donor and transplantation processes can still mean a long wait for those suffering from heart failure. Here, the authors demonstrate the need for alternative ways to treat the infarcted (usually referring to clogging of one of more arteries) heart. And while tissue engineering has pointed the way to freeing many patients from terrible physical suffering and organ donor waiting lists, creating the necessary scaffolds with true biocompatibility has presented obstacles.

The authors have created an engineered cardiac patch meant to be transplanted directly onto the patient’s heart, integrating into the ‘host,’ with excess biomaterials degrading over time. This leaves the cardiac patch, full of live, healthy tissue, regenerating a previously defective heart. Because there is always the threat of rejection when implanting anything into the body though, the authors emphasize the need for appropriate materials:

“Most ideally, the biomaterial should possess biochemical, mechanical, and topographical properties similar to those of native tissues,” state the researchers. “Decellularized tissue‐based scaffolds from different sources meet most of these requirements. However, to ensure minimal response of the immune system, completely autologous materials are preferred.”

The researchers were able to create patient-specific cardiac patches in their recent study, extracting fatty tissue from cardiac patients—and then separating cellular and a-cellular materials.

“While the cells were reprogrammed to become pluripotent stem cells, the extra‐cellular matrix (ECM) was processed into a personalized hydrogel,” stated the researchers.  “Following mixture of the cells and the hydrogel, the cells were efficiently differentiated to cardiac cells to create patient‐specific, immunocompatible cardiac patches.”

In using the patient-specific hydrogel as bioink, the researchers were able to create patches, but ultimately, they were also able to 3D print comprehensive tissue structures that include whole hearts.

An omentum tissue is extracted from the patient and while the cells are separated from the matrix, the latter is processed into a personalized thermoresponsive hydrogel. The cells are reprogrammed to become pluripotent and are then differentiated to cardiomyocytes and endothelial cells, followed by encapsulation within the hydrogel to generate the bioinks used for printing. The bioinks are then printed to engineer vascularized patches and complex cellularized structures. The resulting autologous engineered tissue can be transplanted back into the patient, to repair or replace injured/diseased organs with low risk of rejection.

The authors used two different models in their study, with one serving as proof-of-concept, with pluripotent stem cells (iPSCs)‐derived cardiomyocytes (CMs) and endothelial cells (ECs). The other model relied on:

  • Rat neonatal CMs
  • Human umbilical vein endothelial cells (HUVECs)
  • Lumen‐supporting fibroblasts

One bioink, laden with cardiac cells, printed parenchymal tissue, while the other extruded cells for forming blood vessels. The researchers were successful in 3D printing the patient-specific cardiac patches but found when a higher degree of complexity was necessary for fabrication of organs or other tissues, the hydrogels were not strong enough. They created a new process for organs and more complex tissues where they could print in a free-form manner and cure structures at varying temperatures; they were able to overcome previous challenges and 3D print accurate, personalized structures.

Bioinks characterization. A human omentum a) before and b) after decellularization. c) A personalized hydrogel at room temperature (left) and after gelation at 37 °C (right). d) A SEM image of the personalized hydrogel ultrastructural morphology, and e) a histogram of the fibers diameter. f) Rheology measurements of 1% w/v and 2.5% w/v omentum hydrogels, showing the gelation process upon incubation at 37 °C. g) Stromal cells originated from human omental tissues were reprogrammed to become pluripotent stem cells (red: OCT4, green: Ki67 and blue: nuclei). h) Differentiation to ECs as determined by CD31 (green) and vimentin staining (red). Differentiation to cardiac lineage: i) staining for sarcomeric actinin (red), j) staining for NKX2‐5 (red), and TNNT2 (green). Scale bars: (e) = 10 µm, (g,i,j) = 50 µm, (h) = 25 µm.

This study carries substantial weight, considering the researchers were able to create cellularized hearts with ‘natural architectures.’ This furthers the potential for cardiac transplants after heart failure, along with encouraging the process for drug screening. The authors point out that more long-terms studies and research with animal models are necessary.

“Although 3D printing is considered a promising approach for engineering whole organs, several challenges still remain,” conclude the researchers. “These include efficient expansion of iPSCs to obtain the high cell number required for engineering a large, functioning organ. Additionally, new bioengineering approaches are needed to provide long‐term cultivation of the organs and efficient mass transfer, while supplying biochemical and physical cues for maturation.”

“The printed blood vessel network demonstrated in this study is still limited. To address this challenge, strategies to image the entire blood vessels of the heart and to incorporate them in the blueprint of the organ are required. Finally, advanced technologies to precisely print these small‐diameter blood vessels within thick structures should be developed.”

Imaging of the heart and patch modeling. CT image of a) a human heart and b) left ventricle coronary arteries. c) A model of oxygen concentration profile in an engineered patch. d) Replanning of the model showed better oxygen diffusion, sufficient to support cell viability.

Without good heart health, it is very difficult to survive. Responsible for transporting nutrients, oxygen, and more to cells populating the human body, the heart also removes waste like carbon dioxide and more. 3D printing is assisting scientists and doctors in researching and treating a variety of different diseases and conditions, whether they are using 3D printed metamaterials for fabricating heart valves, creating better cardiac catheters, or experimenting with new types of phantoms.

What do you think of this news? Let us know your thoughts! Join the discussion of this and other 3D printing topics at 3DPrintBoard.com.

Printing thick vascularized tissues. a) A top view of a lumen entrance (CD31; green) in a thick cardiac tissue (actinin; pink). b) A model of a tripod blood vessel within a thick engineered cardiac tissue (coordinates in mm), and c) the corresponding lumens in each indicated section of the printed structure. d) Tissue perfusion visualized from dual viewpoints. e–k) A printed small‐scaled, cellularized, human heart. e) The human heart CAD model. f,g) A printed heart within a support bath. h) After extraction, the left and right ventricles were injected with red and blue dyes, respectively, in order to demonstrate hollow chambers and the septum in‐between them. i) 3D confocal image of the printed heart (CMs in pink, ECs in orange). j,k) Cross‐sections of the heart immunostained against sarcomeric actinin (green). Scale bars: (a,c,h, i,j) = 1 mm, (g) = 0.5 cm, (k) = 50 µm.

[Source / Images: 3D Printing of Personalized Thick and Perfusable Cardiac Patches and Hearts]

Breakthrough 3D Printed Neural Scaffold Could Help Patients with Spinal Cord Injuries Regain Some Functions

Right now, 285,000 people in the US suffer from spinal cord injuries, with roughly 17,000 new injuries each year. 3D printed spinal implants have been shown to help patients recover more easily, and a team of engineers and medical researchers from the University of Minnesota (UMN) have spent the last two years developing an innovative new 3D printed medical device that could help long-term spinal cord injury patients regain some function in the future.

“This is a very exciting first step in developing a treatment to help people with spinal cord injuries. Currently, there aren’t any good, precise treatments for those with long-term spinal cord injuries,” said Ann Parr, MD, PhD, a UMN Medical School Assistant Professor in the Department of Neurosurgery and Stem Cell Institute.

The method involves a 3D printed silicone guide, which acts as a scaffold for special stem cells that are bioprinted directly on top of it. The aim is to surgically implant the guide into the injured part of the spinal cord, and it should act as a bridge between living nerve cells both above and below the area, which could help alleviate pain for patients, in addition to helping them gain control over functions like bladder, bowel, and muscle control again.

“We’ve found that relaying any signals across the injury could improve functions for the patients. There’s a perception that people with spinal cord injuries will only be happy if they can walk again. In reality, most want simple things like bladder control or to be able to stop uncontrollable movements of their legs,” Parr explained. “These simple improvements in function could greatly improve their lives.”

Spinal cord scaffold assembly process: 3D bioprinting cells on silicone scaffolds
allows for in vitro culture of sNPCs and OPCs. (a) Silicone scaffolds are printed with
channels, and (b) cells are dispensed inside the channels. (c) A layer of silicone covers the channels, and (d) scaffolds are placed inside a dish and cultured for 7 days.

The team recently published a paper on their potentially life-changing work, titled “3D Printed Stem-Cell Derived Neural Progenitors Generate Spinal Cord Scaffolds,” in the peer-reviewed scientific journal Advanced Functional Materials.

Fluorescence images of 3D printed cell-laden Matrigel (50%) matrices cultured for 0 (3 hours), 1, and 4 days. Timescale images show (a) sNPCs extending axons, and (b) OPCs exhibiting bi-polar processes.

The abstract reads, “A bioengineered spinal cord is fabricated via extrusion‐based multimaterial 3D bioprinting, in which clusters of induced pluripotent stem cell (iPSC)‐derived spinal neuronal progenitor cells (sNPCs) and oligodendrocyte progenitor cells (OPCs) are placed in precise positions within 3D printed biocompatible scaffolds during assembly. The location of a cluster of cells, of a single type or multiple types, is controlled using a point‐dispensing printing method with a 200 µm center‐to‐center spacing within 150 µm wide channels. The bioprinted sNPCs differentiate and extend axons throughout microscale scaffold channels, and the activity of these neuronal networks is confirmed by physiological spontaneous calcium flux studies. Successful bioprinting of OPCs in combination with sNPCs demonstrates a multicellular neural tissue engineering approach, where the ability to direct the patterning and combination of transplanted neuronal and glial cells can be beneficial in rebuilding functional axonal connections across areas of central nervous system (CNS) tissue damage. This platform can be used to prepare novel biomimetic, hydrogel‐based scaffolds modeling complex CNS tissue architecture in vitro and harnessed to develop new clinical approaches to treat neurological diseases, including spinal cord injury.”

The process begins with any type of adult stem cell, be it blood or skin, and medical researchers use the latest bioengineering techniques to reprogram these into neuronal stem cells. These cells are then 3D printed onto a silicone guide with a unique extrusion-based technology, which can print both the cells and the guide from the same 3D printer.

Michael McAlpine, PhD, UMN Benjamin Mayhugh Associate Professor of Mechanical Engineering in the University’s College of Science and Engineering, said, “This is the first time anyone has been able to directly 3D print neuronal stem cells derived from adult human cells on a 3D-printed guide and have the cells differentiate into active nerve cells in the lab.”

Photograph of customized 3D bioprinting setup.

The 3D printed silicone guide keeps the stem cells alive, so they can change into neurons.

“Everything came together at the right time. We were able to use the latest cell bioengineering techniques developed in just the last few years and combine that with cutting-edge 3D-printing techniques,” said Parr.

The researchers created a prototype implantable guide to help connect the living cells on each side of a damaged spinal cord area, though this task was not without its difficulties.

“3D printing such delicate cells was very difficult. The hard part is keeping the cells happy and alive,” explained McAlpine. “We tested several different recipes in the printing process. The fact that we were able to keep about 75 percent of the cells alive during the 3D-printing process and then have them turn into healthy neurons is pretty amazing.”

With any luck, the team’s next steps in the process will be successful, which should provide some hope for the future to patients with long-term spinal cord injuries.

Co-authors of the paper are Daeha Joung, Vincent Truong, Colin C. Neitzke, Shuang-Zhuang Guo, Patrick J. Walsh, Joseph R. Monat, Fanben Meng, Sung Hyun Park, James R. Dutton, Parr, and McAlpine.

Discuss this and other 3D printing topics at 3DPrintBoard.com or share your thoughts below.